Napo Pharmaceuticals Announces License of Crofelemer to Salix Pharmaceuticals
SAN FRANCISCO, Dec. 10 /PRNewswire/ -- Napo Pharmaceuticals, Inc. ("Napo")
is pleased to announce a collaboration with Salix Pharmaceuticals, Inc.
("Salix") for the license of crofelemer
for all indications in North America,
Europe (excluding certain smaller countries), and Japan, and certain
Napo Obtains Special Protocol Assessment Agreement From FDA for Crofelemer
Napo Pharmaceuticals, Inc., which focuses on the development and commercialization of proprietary pharmaceuticals for the global marketplace in collaboration with local partners , today announced that under the Special Protocol Assessment (SPA) process it has obtained agreement with the United Stat...
Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea
SOUTH SAN FRANCISCO, Calif., April 10 /PRNewswire/ -- Napo
Pharmaceuticals, Inc., (LSE: NAPL and NAPU) is pleased to announce the
positive results of a successfully completed Phase 2 trial for CRO-ID
(crofelemer for the treatment of acute adult infectious diarrhea) conducted
by its partner, Gl...
Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea
SOUTH SAN FRANCISCO, Calif., Dec. 6 /PRNewswire-FirstCall/ -- Napo
Pharmaceuticals, Inc., (LSE: NAPL), which focuses on the development and
commercialization of proprietary pharmaceuticals for the global marketplace
in collaboration with local partners, is pleased to announce that its
Napo Announces Positive Clinical Data Indicating Crofelemer, Could Effectively Treat Cholera
...era. Patients were randomized to
placebo or 125 mg crofelemer
every 6 hours or 250 mg crofelemer
hours in a 1:2:2 randomization scheme. Thi...ree outlier patients, the data
demonstrates that a crofelemer
dose of 125 mg every 6 hours reduced the
Phase 2a Diarrhea Predominant Irritable Bowel Syndrome Results from
2006 Presented at Digestive Disease Week in Washington, D.C.
...ve Disease Week in Washington, D.C. Trine
for the d-IBS indication from Napo in June
2004. T...ldwide development and commercialization rights
for d-IBS. The objective of the trial was to evaluate
the safety and efficacy of crofelemer
in men and women with
The trial was desig...